These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35285490)

  • 1. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.
    Paluri R; Laursen A; Gaeta J; Wang S; Surinach A; Cockrum P
    Oncologist; 2022 Jun; 27(6):e518-e523. PubMed ID: 35285490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    Elias R; Cockrum P; Surinach A; Wang S; Chul Chu B; Shahrokni A
    Oncologist; 2022 Jun; 27(6):469-475. PubMed ID: 35278079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.
    Rochefort P; Lardy-Cleaud A; Sarabi M; Desseigne F; Cattey-Javouhey A; de la Fouchardière C
    Oncologist; 2019 Dec; 24(12):1543-1548. PubMed ID: 31164454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study.
    Hall LA; McKay SC; Halle-Smith J; Soane J; Osei-Bordom DC; Goodburn L; Magill L; Pinkney T; Radhakrishna G; Valle JW; Corrie P; Roberts KJ;
    Br J Cancer; 2023 May; 128(10):1922-1932. PubMed ID: 36959376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.
    Yu KH; Ozer M; Cockrum P; Surinach A; Wang S; Chu BC
    Cancer Med; 2021 Dec; 10(24):8934-8943. PubMed ID: 34811961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a prognostic nomogram for metastatic pancreatic ductal adenocarcinoma integrating marital status.
    Ma X; Guo J; Zhang C; Bai J
    Sci Rep; 2022 May; 12(1):7124. PubMed ID: 35504988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy.
    Colloca GA; Venturino A; Guarneri D
    Clin Exp Metastasis; 2019 Dec; 36(6):519-525. PubMed ID: 31578654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma.
    Oviedo P; Burns S; Chen WP; Mandl HK; Rosso C; Radgoudarzi N; Crosetti A; Zamora S; Perry LM; Bold RJ; Labora AN; Donahue TR; Maker A; Valerin JB; Zell JA; White RR
    J Surg Oncol; 2024 Aug; 130(2):276-283. PubMed ID: 38894577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience.
    Bailey RE; Surapaneni PK; Core J; Vidal LLC; LeGout J; Ritchie C; Frey G; McKinney JM; Sella D; Paz-Fumagalli R; Toskich B; Mody K
    J Gastrointest Oncol; 2019 Aug; 10(4):688-694. PubMed ID: 31392049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
    Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
    Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the COVID-19 pandemic on patients with pancreatic cancer.
    Salirrosas O; Vega EA; Panettieri E; Salehi O; Kozyreva O; Harandi H; Ganta S; Conrad C
    J Gastrointest Surg; 2024 Jun; 28(6):830-835. PubMed ID: 38570231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Surgical Resection Significantly Prolong the Long-Term Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma? A Cross-Sectional Study Based on 18 Registries.
    Li Z; Zhang X; Sun C; Li Z; Fei H; Zhao D
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center.
    Ellithi M; Abdallah M; Fischer M; Ailts I; Fanta J; Waligoske K; Bell M; Nelson ME; Bleeker J
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):479-486. PubMed ID: 35400291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
    Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
    Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993-2013.
    Golan T; Sella T; Margalit O; Amit U; Halpern N; Aderka D; Shacham-Shmueli E; Urban D; Lawrence YR
    J Natl Compr Canc Netw; 2017 Aug; 15(8):1022-1027. PubMed ID: 28784864
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study.
    Moffat GT; Coyne Z; Albaba H; Aung KL; Dodd A; Espin-Garcia O; Moura S; Gallinger S; Kim J; Fraser A; Hutchinson S; Moulton CA; Wei A; McGilvray I; Dhani N; Jang R; Elimova E; Moore M; Prince R; Knox J
    Curr Oncol; 2024 May; 31(5):2589-2597. PubMed ID: 38785475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.